Latest news with #Goldstein
Yahoo
19 hours ago
- Entertainment
- Yahoo
'I Don't Want To Sound Woo Woo': Ted Lasso's Brett Goldstein Drops An F-Bomb While Explaining Why He Warmed Up To The Idea Of Making Season 4
When you buy through links on our articles, Future and its syndication partners may earn a commission. About two years after Ted Lasso's Season 3 finale and the presumed ending of the Apple TV+ comedy, it was announced that the series will indeed be returning. It's unknown when, and we don't know who will be part of it yet, but the fact that Season 4 is actually happening is cause for celebration. For a while, it was hard to tell if another season was possible, but luckily, fans won't have to wonder any longer. Now, Roy Kent himself, Brett Goldstein, is revealing why he eventually warmed up to doing another season, and his explanation obviously included an f-bomb. Not only is Goldstein part of the Ted Lasso cast as Roy Kent, but he is also a writer on the show. So he's part of the team that's making decisions about where this next story will go. Now, while talking about Season 4 of Ted Lasso on Vulture's Good One podcast with Jesse David Fox, the Emmy winner opened up about why he warmed up to the idea of returning to Richmond, saying: I think it's to do with the people and the characters and the actors. You have this plan, but then this world starts to build in front of you, and you fall in love with things you didn't know you'd fall in love with. I don't want to sound woo woo, but I do mean this. You still have to stay open to the signs. You always have a plan, but the plan will change because someone is different and what everyone brings. So yes, we've stuck to that plan, but there's so many new, wonderful things within it, that it's like, 'Oh, we could [do more]. I think, I don't know, do you want to hang out in that world anymore? And if so, it's only worth doing if you're going to do it as well [as you've done] if not better.' For a while, it was assumed that Season 3 of Ted Lasso was it, but even though some stories were wrapped up, it was clear that the door wasn't fully closed, and there was potential for a fourth installment or spinoffs. Not only was there still interest within the cast, but fans probably kept their hopes up, too, that something would happen, no matter how much time had passed. Now, even though not much has been shared about what exactly Ted Lasso Season 4 will consist of, it's clear that there are some exciting ideas churning, and Goldstein dropped an appropriate f-bomb while explaining it: When the idea is there, if you remain open to it and the idea comes, you're like, 'Oh! That's a good one.' But then you're like, 'Fuck! Maybe there is more.' Apple TV Plus: 7-Day Free TrialBELIEVE it, people, you can get Apple TV+ for one week for free, which gives you enough time to binge the first three seasons of Ted Lasso. Then, make sure to keep it around for $9.99 per month so you can watch Season 4 whenever it comes out. View Deal When previously asked about returning for Ted Lasso Season 4, Goldstein used an analogy about a dead cat coming back to life, and it was weirdly fitting. You have to move on, but you still hope and pray that somehow it gets brought back to life because a part of you knows this shouldn't be the end. In the case of the cat, it wasn't dead. And in the case of Ted Lasso, even after saying goodbye, they still returned for another round. Now, the wait for Season 4 could be a long one, but fans have already been waiting for almost two years for news on a fourth season. So, waiting a little bit longer for it to actually come out shouldn't be too painful. Additionally, more news about the new season is expected to be released as they continue developing it, so hopefully, we'll learn more about the cast and the plot sooner rather than later. Ted Lasso continues to be one of the best shows on Apple TV+, so it's not surprising that it's finally coming back. It's unknown when it will eventually return, but for now, fans can watch the first three seasons with an Apple TV+ subscription.
Medscape
a day ago
- Health
- Medscape
New Guidance on the Use of Unproven Neurologic Therapeutics
A new position statement outlining guiding principles for navigating the use of unproven therapies for neurologic conditions that lack approval from the FDA or robust scientific evidence has been released by the American Academy of Neurology (AAN). The statement is intended to support informed conversations between clinicians, patients, and policymakers about emerging or unproven treatments. While it includes examples of such therapies, the document stops short of offering clinical recommendations. The use of emerging neurologic therapies not yet supported by science has been 'an ongoing concern,' with patients often asking providers about these therapies, the statement's lead author Larry B. Goldstein, MD, professor and chair of the Department of Neurology and associate dean for Clinical Research, University of Kentucky, Lexington, Kentucky, told Medscape Medical News. Developed in response to requests from AAN members seeking guidance on emerging therapeutics, the statement outlines guiding principles to support clinical and policy discussions. It was published online on June 25 in Neurology. Lack of FDA-Approved Options Many neurologic diseases have no available FDA-approved therapeutic options and no, or limited, evidence-based treatments. However, many potential treatments, both synthetic and naturally occurring, may be in varying stages of expert evaluation for neurologic conditions. Psychedelics have emerged as potential therapies for pain disorders such as cluster headache, as well as psychiatric conditions including major depression, posttraumatic stress disorder (PTSD), generalized anxiety, and substance use disorders. However, data on psychedelics' risks and benefits for these indications are limited. The AAN committee cites the example of midomafetamine combined with psychotherapy for the treatment of PTSD. Although this approach has generated interest, an FDA advisory committee recently recommended against its approval, citing significant methodological flaws in the supporting studies and advising the FDA to reject the Investigational New Drug Application. 'This illustrative example highlights the need for rigorous, placebo-controlled, double-blind trials to adequately test the effectiveness of these therapies while exhaustively documenting adverse events to characterize patient safety issues,' the statement's authors noted. The AAN supports the FDA-accelerated review of novel therapeutics for neurologic conditions 'when this process is appropriate,' said Goldstein. Off-Label Use The statement also addresses the expanded use of therapies beyond their original FDA-approved indications — for example, the off-label use of alteplase for thrombolysis in ischemic stroke patients treated 3-4.5 hours after they were last known to be well, as well as the use of tenecteplase in select cases of acute ischemic stroke. Goldstein noted that these examples reflect issues commonly encountered in hospitals nationwide. 'The AAN supports the off-label use of FDA-approved therapies in settings in which the high-quality evidence indicates that the benefit of the therapy outweighs the risks with shared decision-making between the patient and physician in the model of informed consent,' the statement authors noted. Another example is natalizumab, a humanized IgG4κ monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (MS). The drug was initially withdrawn from the market following reports of progressive multifocal leukoencephalopathy. However, it was later reintroduced, as some patients with MS have no alternative therapies to effectively manage their disease. Physician-patient discussions about unproven therapies might include situations where patients are considering their 'Right to Try.' Signed into law in 2018, the Right to Try Act allows individuals with a terminal illness who have tried all approved treatments and who are unable to participate in a clinical trial to receive an experimental treatment. The statement also addresses the issue of adverse events reported after FDA approval. For example, the statin cerivastatin was approved for cholesterol reduction but was withdrawn from clinical use following reports of deaths and hospitalizations. These cases, said Goldstein, illustrate the complexity of this issue. 'It's particularly challenging because healthcare providers must be constantly aware of new data that may become available as therapeutics enter general use after FDA approval,' said Goldstein. In cases where a therapy is approved but carries significant risks or an incomplete adverse event profile, the statement advises that the AAN should generally refrain from taking a definitive position until further review by the FDA is completed. Unproven 'Treatments' The authors also address the use of therapeutics with limited or no supporting data, many of which have been popularized on social media, to treat or prevent conditions such as dementia. Such use not only exposes patients to unknown risks but may also discourage them from pursuing evidence-based treatments or participating in clinical trials that could offer potential benefits, Goldstein noted. When seeing patients, healthcare providers should discuss potential participation in a relevant trial and ask more detailed questions about the use of unproven therapies, he said. 'Physicians should routinely not only confirm their patient's prescribed medications but also ask about any other substances they may be using. Some, including certain supplements, may have potential toxicities or interactions with prescribed medications.' Discussions between neurologists and patients about unproven therapies are becoming increasingly relevant. 'In the current climate of unfiltered, at times incorrect or misinterpreted information, having a trustworthy source of fact-based advice is critically important,' said Goldstein. 'The neurologist brings particular expertise and training related to neurological disorders and what is known about the risks and benefits of potential treatments to help inform patient decisions,' he added. The AAN policy statement offers 'a framework' to guide neurologists in their role as patient advocates, Goldstein added. Although it does not address specific treatments, it does provide a structure for conversations with patients, said Goldstein.
Associated Press
a day ago
- Health
- Associated Press
SeaStar's QUELIMMUNE Can Cut Pediatric Sepsis Deaths In Half
By Meg Flippin Benzinga DETROIT, MICHIGAN - June 27, 2025 ( NEWMEDIAWIRE ) - SeaStar Medical Holding Corp. (NASDAQ: ICU), the commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, has made a lot of inroads on that front with QUELIMMUNE. A humanitarian medical device, QUELIMMUNE treats pediatric patients with acute kidney injury or AKI due to sepsis or a septic condition. The QUELIMMUNE therapy received U.S. Food and Drug Administration approval in 2024 after clinical trials showed it could cut mortality in half from 50% to 25%. 'QUELIMMUNE is designed to target the innate immune response. When patients get very sick, it becomes very dysregulated and cells go haywire and trigger something called the cytokine storm,' said Dr. Kevin Chung, MD, Chief Medical Officer at SeaStar Medical. 'The QUELIMMUNE device is designed specifically to target the cytokine storm at the source of the storm and it is associated with really good outcomes, especially in the pediatric population where mortality was cut in half from 50% to 25%.' From The Golf Course To The ICU That was the case for Kurt, a young student and avid golfer who has won multiple golf awards even though he underwent two open-heart surgeries before his sixth birthday. Knowing at an early age that he couldn't compete in the sports other kids were playing, Kurt picked up golf and never looked back. But over the years, Kurt faced doctor visits and surgeries, culminating in a near-death experience. At the time, Kurt was being treated at Cincinnati Children's Hospital Medical Center, where Dr. Stuart L. Goldstein, MD, the lead researcher for QUELIMMUNE's two trials that led to the device's FDA approval, worked. Kurt went in for a planned surgery to address an artificial replacement from his pulmonary to aortic valve, but had to be opened up again two days later as a result of blood leaking from his heart at the site of surgery. Kurt was put on a ventilator and went into multiple-organ failure, caught hospital pneumonia, and ultimately endured a 12-day coma. He developed AKI and respiratory failure, and doctors prepared to put him on ECMO (Extracorporeal Membrane Oxygenation), a more invasive type of support. But Dr. Goldstein spoke with the on-staff cardiologist and Kurt's family and suggested that the QUELLIMUNE therapy would be helpful for him. 'Kurt just started to turn around within 24 to 48 hours and did not require ECMO. Kurt left the ICU within two to three weeks and resumed going back to school and golfing,' says Dr. Goldstein. 'It was quite dramatic and is emblematic of when we see this work, which is far more often than not, patients turn around really really quickly when you wouldn't expect them to.' A Christmas Miracle For Kurt's father, David, the QUELIMMUNE therapy was a last-ditch effort to save his son, who had been languishing in the ICU for eleven days. Every night, the doctors would offer up different therapies and treatment ideas to stop his son's organs from failing and as luck would have it, one evening David and his nephew, who is also a doctor, ran into Dr. Goldstein outside of his son's room. Dr. Goldstein said he thought the QUELIMMUNE therapy could help with the inflammation and the family decided, given the apparently bleak prognosis, to give it a try, recalls David. From day two on, the inflammatory markers improved and continued to get a lot better. 'The inflammatory markers improved every day,' says David. His son was woken from the coma on day six of treatment, December 24. 'It was a Christmas miracle. He was awake and his numbers were improving,' his father said. Kurt had a tough recovery ahead of him when he woke up. He entered the hospital weighing 150 pounds and left at about 120 pounds. But by the beginning of March, he had regained his strength and energy and was golfing again. That is one of the other aspects of the QUELIMMUNE therapy that astonishes Dr. Goldstein, and makes him so optimistic that the device can treat other children with AKI. Typically 10% to 30% of pediatric patients who survive an AKI episode require chronic dialysis, but Kurt didn't. 'It is nothing I've seen before in clinical medicine in the last quarter century,' said Dr. Goldstein. Featured image fromShutterstock This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. This content was originallypublished on further disclosureshere.
Associated Press
a day ago
- Health
- Associated Press
EXECUTIVE INTERVIEW: SeaStar CMO And Pediatric Specialist Talk About Promising Therapy To Treat Pediatric AKI
By Meg Flippin, Benzinga DETROIT, MICHIGAN - June 27, 2025 ( NEWMEDIAWIRE ) - Dr. Kevin Chung, Chief Medical Officer at SeaStar Medical Holding Corporation (NASDAQ: ICU) and Dr. Stuart L. Goldstein, MD, from Cincinnati Children's Hospital Medical Center, were recently guests on Benzinga's All-Access. The two were on hand to discuss QUELIMMUNE, SeaStar Medical's humanitarian medical device that was granted U.S. FDA approval to treat pediatric patients with acute kidney injury (AKI) due to sepsis or a septic condition. Dr. Goldstein was the chief investigator for the two studies that led to the FDA approval. Pediatric AKI is a sudden episode of kidney failure that happens within a few hours or days. It can be brought on by several conditions including sepsis, severe trauma and surgery. AKI can cause hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from hyperinflammation in AKI can progress to other organs, such as the heart or liver and potentially lead to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, patients may face complications including chronic kidney disease or end-stage renal disease requiring dialysis. Treating The Untreatable There are about 4,000 cases of pediatric AKI each year in the U.S., Dr. Chung shared, and the mortality rate among those patients is high at 50%. QUELIMMUNE, which was granted approval under a Humanitarian Device Exemption (HDE) by the FDA in February 2024, was developed to treat AKI among children. 'QUELIMMUNE is designed to target the innate immune response. When patients get very sick, it becomes very dysregulated and cells go haywire and trigger something called the cytokine storm,' said Dr. Chung in the interview. 'The QUELIMMUNE device is designed specifically to target the cytokine storm at the source of the storm, and it is associated with really good outcomes, especially in the pediatric population where mortality was cut in half from 50% to 25%.' That reduction in mortality is quite promising given that while there have been medical advances in treating AKI over the years, including targeted medications, nothing has been able to help patients with AKI so severe that it requires dialysis or inflammation so bad that it has increased the chance of death, Dr. Goldstein noted. But QUELIMMUNE proved very effective in trials, surprising even Dr. Goldstein, and that is why it received FDA approval and is being used in hospitals around the country. 'What we saw as we started the initial trial is kids that had a 50% chance of mortality, not only did that go in half, but we saw a dramatic improvement almost in 24 to 48 hours, which was quite shocking to us frankly,' said Dr. Goldstein. What's more, of the patients who survived, they were off dialysis sixty to ninety days later, something unheard of. Typically, 10-30% of pediatric patients who survive an AKI episode require chronic dialysis, Dr. Goldstein shared. 'It's a dramatic improvement that you see almost within the first one to two days. It is nothing I've seen before in clinical medicine in the last quarter century,' he stated further. Looking Beyond Pediatric AKI In addition to treating pediatric AKI, SeaStar is currently engaged in a trial evaluating the safety and efficacy of QUELIMMUNE for treating adult AKI. The study has over 100 patients enrolled, and the company is shooting for a total of 200. Beyond that, Dr. Chung said the idea is to use QUELIMMUNE for any condition in which the innate immune system is disturbed. 'The therapy itself is organ- and disease-agnostic,' said Dr. Chung, noting the company has six Breakthrough Device Designations from the FDA. BDD is designed to encourage speedier development of certain medical devices when there is a reasonable chance of providing a better treatment or diagnosis than the current standard of care. The BDD status is reserved for those diseases that are life-threatening or can cause irreversibly debilitating effects on patients. 'Other disease states are definitely going to be next,' Dr. Chung told Benzinga. Featured image from Shutterstock . This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. This content was originally published on Benzinga. Read further disclosures here.
New York Post
a day ago
- Health
- New York Post
I'm ‘Dr. Butthole' — beware this warning sign that could lead to a scary ‘silent disease'
That's a bummer! Anal cancer is on the rise, particularly among white and Hispanic women over the age of 65. The lifetime risk of developing anal cancer is around 1 in 500, according to the American Cancer Society, which predicts about 11,000 new cases and 2,000 deaths this year. Dr. Evan Goldstein, an NYC-based anal surgeon known colloquially as Dr. Butthole and 'the bottom whisperer,' cautions about a warning sign that can increase the risk of getting diagnosed with this 'silent disease.' Advertisement 4 Dr. Evan Goldstein, an NYC-based anal surgeon, wrote 'Butt Seriously: The Definitive Guide to Anal Health, Pleasure and Everything In Between.' Courtesy of Dr. Evan Goldstein 'Anal cancer stems from the HPV virus and, for many, from the development of anal warts,' Goldstein, founder and CEO of Bespoke Surgical and Future Method, told The Post. About 90% of anal cancers are linked to infection with the human papillomavirus (HPV). Advertisement HPV is a group of over 200 related viruses primarily spread through skin-to-skin contact. The Centers for Disease Control and Prevention estimates that 85% of people will get HPV at some point. 4 This man has a skin lesion from human papillomavirus. Untreated skin lesions caused by HPV can potentially progress to anal cancer. Parilov – Certain strains of HPV are known to cause anal warts — and these benign growths can be difficult to distinguish. Advertisement They may present as a single bump in the anal region or as a cluster that resembles cauliflower. Most are raised, but some are flat. 'Many think they are just skin tags and then find out it's anal warts from HPV,' said Goldstein, author of 'Butt Seriously: The Definitive Guide to Anal Health, Pleasure and Everything In Between.' 'They can be painful and itchy and lead to bleeding.' Advertisement Some patients don't have any symptoms and may not know they have anal warts. Treatment includes topical medications, cryotherapy or surgical removal. The body's immune system often clears HPV infections naturally, usually within a few years, but some persist. 4 Anal warts can be itchy and painful or not have any symptoms. Wasan – Chronic infections with certain high-risk types of HPV can cause changes in anal cells, potentially leading to precancerous lesions. If left untreated, they can progress to invasive anal cancer. Symptoms of anal cancer include rectal bleeding, a lump near the anus, pain or pressure in the anal area, itching or discharge from the anus and changes in bathroom habits. In the early stages, there may not be noticeable symptoms. 'The idea is to catch this early with early detection anal pap smears and full anoscopy (in and out visualization with a camera and high-resolution scope) with an appropriate anal practitioner,' Goldstein advised. Advertisement When found early, anal cancer is often highly treatable. Five-year survival rates after diagnosis hover around 64%. 4 Goldstein recommends seeing an anal specialist, especially if engaging in anal play, for internal and external evaluations and anal pap smears that can detect changes in the cells lining the anal canal. theartofphoto – Prevention is key. All teens should get Gardasil 9, a series of shots that can protect against certain types of HPV infections, Goldstein said. Researchers suggest that the recent anal cancer surge in older women could be due to these women being beyond the age recommended for HPV inoculation when it became widely available in 2006. Advertisement Goldstein also recommends seeing an anal specialist, especially if engaging in anal play, for internal and external evaluations and anal pap smears that can detect changes in the cells lining the anal canal. 'The more we talk about [anal health] and standardize yearly evaluations, similar to gynecology appointments, the better all of us will be,' he said.
